Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
No curative therapies for recessive dystrophic epidermolysis bullosa (RDEB) are currently available. In this study, we sought to develop novel therapies for this intractable disease targeting at the COL7A1 promoter. First, we constructed a vector containing the luc2P gene driven by the COL7A1 promoter and generated stable cell lines carrying the gene construct. Compound library screening using the stable cells identified a dozen of 'hits'. However, further screening showed that most of them are 'false-positive'. We are now testing these compounds using normal human epidermal keratinocytes to see if they up-regulate the COL7A1 promoter.
|